Table 3 Univariate and multivariate... | American Society of Hematology

Table 3

Univariate and multivariate analyses for survival in chronic phase

	Univariate			Multivariate
	Adverse	HR	P	HR	P
Age, y	Older; continuous	1.01	.002	1.01	< .001
Sex	Male vs female	1.08	.38	1.25	.03
Splenomegaly	Yes vs no	1.85	< .001	1.09	.51
Hemoglobin, g/dL	Lower; continuous	0.88	< .001	0.94	.02
WBC count, × 10⁹/L)	Higher; continuous	1.003	< .001	0.999	.31
Platelet count, × 10⁹/L)	Lower; continuous	1.004	< .001	1.00	.41
Peripheral blasts, %	Higher; continuous	1.14	< .001	0.995	.83
Peripheral basophils, %	Higher; continuous	0.98	.09	0.98	.17
BM blasts, %	Higher continuous	1.07	< .001	1.06	.02
BM basophils, %	Higher; continuous	1.05	.004	1.08	< .001
Sokal	Intermediate vs low	1.84	< .001	1.28	.07
Sokal	High vs low	2.23	< .001	1.10	.62
Year of therapy	Continuous	0.93	< .001	0.925	< .001

	Univariate			Multivariate
	Adverse	HR	P	HR	P
Age, y	Older; continuous	1.01	.002	1.01	< .001
Sex	Male vs female	1.08	.38	1.25	.03
Splenomegaly	Yes vs no	1.85	< .001	1.09	.51
Hemoglobin, g/dL	Lower; continuous	0.88	< .001	0.94	.02
WBC count, × 10⁹/L)	Higher; continuous	1.003	< .001	0.999	.31
Platelet count, × 10⁹/L)	Lower; continuous	1.004	< .001	1.00	.41
Peripheral blasts, %	Higher; continuous	1.14	< .001	0.995	.83
Peripheral basophils, %	Higher; continuous	0.98	.09	0.98	.17
BM blasts, %	Higher continuous	1.07	< .001	1.06	.02
BM basophils, %	Higher; continuous	1.05	.004	1.08	< .001
Sokal	Intermediate vs low	1.84	< .001	1.28	.07
Sokal	High vs low	2.23	< .001	1.10	.62
Year of therapy	Continuous	0.93	< .001	0.925	< .001